Vantobra (previously Tobramycin PARI)



This medicine is authorised for use in the European Union.


Vantobra is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis.

Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections. P. aeruginosa is a frequent cause of infections in cystic fibrosis patients.

Vantobra is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, tobramycin; however, Vantobra has a higher amount of the active substance. The reference medicine for Vantobra is Tobi.

This EPAR was last updated on 22/09/2023

Authorisation details

Product details
Vantobra (previously Tobramycin PARI)
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Respiratory Tract Infections
  • Cystic Fibrosis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Pari Pharma GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Moosstrasse 3
82319 Starnberg

Product information

15/09/2023 Vantobra (previously Tobramycin PARI) - EMEA/H/C/005086 - R/0009

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

How useful was this page?

Add your rating